YU64202A - Postupak za pripremanje klaritromicina i intermedijera klaritromicina, klaritromicina u osnovi bez oksima i farmaceutskog preparata koji ga sadrži - Google Patents

Postupak za pripremanje klaritromicina i intermedijera klaritromicina, klaritromicina u osnovi bez oksima i farmaceutskog preparata koji ga sadrži

Info

Publication number
YU64202A
YU64202A YU64202A YUP64202A YU64202A YU 64202 A YU64202 A YU 64202A YU 64202 A YU64202 A YU 64202A YU P64202 A YUP64202 A YU P64202A YU 64202 A YU64202 A YU 64202A
Authority
YU
Yugoslavia
Prior art keywords
clarithromycin
oxime
processes
protected silylated
preparing
Prior art date
Application number
YU64202A
Other languages
English (en)
Inventor
Ilya Avrutov
Igor Lifshitz
Elizabeth Lewiner
Original Assignee
Teva Pharmaceutical Industries Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd. filed Critical Teva Pharmaceutical Industries Ltd.
Publication of YU64202A publication Critical patent/YU64202A/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C07F7/1872—Preparation; Treatments not provided for in C07F7/20
    • C07F7/1892—Preparation; Treatments not provided for in C07F7/20 by reactions not provided for in C07F7/1876 - C07F7/1888

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Predmetni pronalazak odnosi se na postupke za pripremanje zasticenog sililatiranog oksima klaritromicina, pozeljno 6-O-metil-2',4"-bis(trimetilsilil)-eritromicin A 9-O-(2-metoksiprop-2-il)oksima ("S_MOP oksim"), i na pretvaranje zasticenog sililatiranog oksima klaritromicina, pozeljno S-MOP oksima, u klaritromicin. Postupak za pripremanje zasticenog sililatiranog oksima klaritromicina u skiadu sa predmetnim pronalaskom, ukljucuje reagovanje derivata sililatiranog oksima sa metilirajucim ciniocem u prisustvu najmanje jednog rastvaraca i baze, gde rastvarac sadrzi metil tertbutil etar. Postupak za pretvaranje zasticenog sililatiranog oksima klaritromicina u klaritromicin prema predmetnom pronalasku ukljucuje reagovanje zasticenog sililatiranog oksima klaritromicina sa etanolom i vodom pri odnosu etanola prema vodi od oko 1:1, u prisustvu kiseline i deoksimatirajuceg cinioca i hladjenje reakcione mesavine pre dodavanja natrijum hidroksida, gde se proces odigrava bez bilo kakvog dodavanja adicione vode. Dalje postupak za pretvaranje zasticenog sililatiranog oksima klaritromicina, u klaritromicin ukljucuje zagrevanje mesavine zasticenog sililatiranog oksima klaritromicina, kiseline i deoksimatirajuceg cinioca u rastvaracu etanol/voda do refluksa tokom vise od 4 casa, sa dvostrukim dodavanjem deoksimatirajuceg cinioca da se produkuje klaritromlcin u osnovi bez oksima.
YU64202A 2000-02-29 2000-12-15 Postupak za pripremanje klaritromicina i intermedijera klaritromicina, klaritromicina u osnovi bez oksima i farmaceutskog preparata koji ga sadrži YU64202A (sh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18588800P 2000-02-29 2000-02-29
US18912000P 2000-03-14 2000-03-14
US21323900P 2000-06-22 2000-06-22

Publications (1)

Publication Number Publication Date
YU64202A true YU64202A (sh) 2005-03-15

Family

ID=27392028

Family Applications (1)

Application Number Title Priority Date Filing Date
YU64202A YU64202A (sh) 2000-02-29 2000-12-15 Postupak za pripremanje klaritromicina i intermedijera klaritromicina, klaritromicina u osnovi bez oksima i farmaceutskog preparata koji ga sadrži

Country Status (15)

Country Link
US (3) US6617436B2 (sh)
EP (1) EP1313486A1 (sh)
JP (1) JP2004509062A (sh)
KR (1) KR20030047873A (sh)
AU (2) AU2578701A (sh)
CA (1) CA2401571A1 (sh)
CZ (1) CZ20023167A3 (sh)
HR (1) HRP20020709A2 (sh)
HU (1) HUP0302466A2 (sh)
IL (1) IL151496A0 (sh)
IS (1) IS6531A (sh)
PL (1) PL366021A1 (sh)
SK (1) SK13722002A3 (sh)
WO (1) WO2001064224A1 (sh)
YU (1) YU64202A (sh)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020070991A (ko) * 1999-12-16 2002-09-11 테바 파마슈티컬 인더스트리즈 리미티드 클라리트로마이신 다형체 및 신규의 다형체 ⅳ의 제조 방법
HUP0204252A3 (en) * 2000-01-11 2003-04-28 Teva Pharma Process for preparing clarithromycin polymorphs and pharmaceutical compositions containing them
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
WO2001064224A1 (en) * 2000-02-29 2001-09-07 Teva Pharmaceutical Industries Ltd. Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same
KR20030011797A (ko) * 2000-03-28 2003-02-11 바이오케미 게젤샤프트 엠베하 맛이 차폐된 과립형 입자
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
AU2004258949B2 (en) 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
AU2004258944B2 (en) 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
CA2533292C (en) 2003-07-21 2013-12-31 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
JP2007502296A (ja) 2003-08-11 2007-02-08 アドバンシス ファーマスーティカル コーポレイション ロバストペレット
US8062672B2 (en) 2003-08-12 2011-11-22 Shionogi Inc. Antibiotic product, use and formulation thereof
WO2005023184A2 (en) * 2003-08-29 2005-03-17 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
WO2005027877A1 (en) 2003-09-15 2005-03-31 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
WO2006014427A1 (en) 2004-07-02 2006-02-09 Advancis Pharmaceutical Corporation Tablet for pulsed delivery
JP2009500356A (ja) * 2005-07-07 2009-01-08 エラン ファーマ インターナショナル リミテッド ナノ粒子クラリスロマイシン製剤
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
WO2009023191A2 (en) * 2007-08-09 2009-02-19 Teva Pharmaceutical Industries Ltd. An improved process for the preparation of clarithromycin
CN102417532A (zh) * 2011-12-20 2012-04-18 浙江国邦药业有限公司 一种泰利霉素关键中间体5-德胺糖基-6-o-甲基红霉素的合成方法
CN102718821B (zh) * 2012-06-27 2014-12-03 浙江国邦药业有限公司 一种克拉霉素合成过程中甲基化反应以及甲基化试剂的回收套用方法
CN103880901A (zh) * 2012-12-23 2014-06-25 菏泽市方明制药有限公司 一种克拉霉素中间甲化物的制备方法
CN106905204B (zh) * 2017-02-24 2018-07-20 杭州新桂实业有限公司 一种克拉霉素合成过程中甲基化反应溶剂的回收套用方法
CN108117573A (zh) * 2017-12-26 2018-06-05 宁夏启元药业有限公司 4"-o-（三甲基硅）红霉素a 9-o-（1-乙氧基-1-甲基乙基）肟的合成方法

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US669236A (en) * 1900-02-16 1901-03-05 Frank M Garland Automatic machine-gun.
US3922379A (en) * 1973-12-17 1975-11-25 Abbott Lab Microencapsulation process
FR2473525A1 (fr) 1980-01-11 1981-07-17 Roussel Uclaf Nouvelles oximes derivees de l'erythromycine, leur procede de preparation et leur application comme medicaments
US4331803A (en) 1980-06-04 1982-05-25 Taisho Pharmaceutical Co., Ltd. Novel erythromycin compounds
DE3174858D1 (en) * 1980-12-25 1986-07-24 Fujitsu Ltd Nonvolatile semiconductor memory device
JPS60214796A (ja) 1984-04-06 1985-10-28 Taisho Pharmaceut Co Ltd ６−０−メチルエリスロマイシン類の製法
JPS61103890A (ja) 1984-10-26 1986-05-22 Taisho Pharmaceut Co Ltd ６−０−メチルエリスロマイシンａ誘導体
EP0188040B1 (en) * 1985-01-11 1991-08-14 Abbott Laboratories Limited Slow release solid preparation
US4670549A (en) 1985-03-18 1987-06-02 Taisho Pharmaceutical Co., Ltd. Method for selective methylation of erythromycin a derivatives
US4672056A (en) 1985-11-12 1987-06-09 Abbott Laboratories Erythromycin A derivatives and method of use
US4640910A (en) 1985-11-12 1987-02-03 Abbott Laboratories Erythromycin A silylated compounds and method of use
KR960000434B1 (ko) 1986-12-17 1996-01-06 다이쇼 세이야꾸 가부시끼가이샤 에리스로마이신 a유도체 및 그의 제조 방법
US4808411A (en) * 1987-06-05 1989-02-28 Abbott Laboratories Antibiotic-polymer compositions
GB8721165D0 (en) 1987-09-09 1987-10-14 Beecham Group Plc Chemical compounds
JP2751385B2 (ja) 1988-05-19 1998-05-18 大正製薬株式会社 エリスロマイシンａオキシム及びその塩の製造方法
IT1246383B (it) * 1990-04-17 1994-11-18 Eurand Int Metodo per il mascheramento del sapore di farmaci
GB9120131D0 (en) * 1991-09-20 1991-11-06 Glaxo Group Ltd Medicaments
JP3265680B2 (ja) * 1992-03-12 2002-03-11 大正製薬株式会社 経口製剤用組成物
IL105155A (en) * 1992-04-24 1999-05-09 Astra Ab Synergistic combination of an inhibitor of gastric acid secretion with an acid-breaking antibiotic
ATE217789T1 (de) * 1992-06-04 2002-06-15 Smithkline Beecham Corp Angenehm schmeckende pharmazeutische zusammensetzungen
US5919489A (en) * 1995-11-01 1999-07-06 Abbott Laboratories Process for aqueous granulation of clarithromycin
US5756473A (en) 1995-11-21 1998-05-26 Abbott Laboratories 6-O-methyl erythromycin D and process for making
US5872229A (en) 1995-11-21 1999-02-16 Abbott Laboratories Process for 6-O-alkylation of erythromycin derivatives
US5705190A (en) * 1995-12-19 1998-01-06 Abbott Laboratories Controlled release formulation for poorly soluble basic drugs
US5998194A (en) * 1995-12-21 1999-12-07 Abbott Laboratories Polyketide-associated sugar biosynthesis genes
US5719272A (en) 1996-04-02 1998-02-17 Abbott Laboratories 2'-protected 3'-dimethylamine, 9-etheroxime erythromycin A derivatives
US5837829A (en) 1996-04-02 1998-11-17 Abbott Laboratories 9-oximesilyl erythromycin a derivatives
US5808017A (en) 1996-04-10 1998-09-15 Abbott Laboratories Process for preparing erythromycin A oxime
AUPN969796A0 (en) * 1996-05-07 1996-05-30 F.H. Faulding & Co. Limited Taste masked liquid suspensions
EP0915899B1 (en) 1996-07-29 2004-08-04 Abbott Laboratories Preparation of crystal form ii of clarithromycin
US5858986A (en) 1996-07-29 1999-01-12 Abbott Laboratories Crystal form I of clarithromycin
US5844105A (en) 1996-07-29 1998-12-01 Abbott Laboratories Preparation of crystal form II of clarithromycin
US5972389A (en) * 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
US5945405A (en) 1997-01-17 1999-08-31 Abbott Laboratories Crystal form O of clarithromycin
US5864023A (en) 1997-02-13 1999-01-26 Abbott Laboratories 3'-N'oxide, 3'-n-dimethylamine, 9-oxime erythromycin a derivatives
US6010718A (en) * 1997-04-11 2000-01-04 Abbott Laboratories Extended release formulations of erythromycin derivatives
US6551616B1 (en) * 1997-04-11 2003-04-22 Abbott Laboratories Extended release formulations of erythromycin derivatives
US20050064033A1 (en) * 1997-04-11 2005-03-24 Notario Gerard F. Extended release formulations of erythromycin derivatives
US6635280B2 (en) * 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
JP4083818B2 (ja) * 1997-06-06 2008-04-30 ディポメド，インコーポレイティド 高度可溶性薬物の制御された放出のための胃滞留性の経口薬物投与形
US5869098A (en) * 1997-08-20 1999-02-09 Fuisz Technologies Ltd. Fast-dissolving comestible units formed under high-speed/high-pressure conditions
US5929219A (en) * 1997-09-10 1999-07-27 Abbott Laboratories 9-hydrazone and 9-azine erythromycin derivatives and a process of making the same
US5852180A (en) 1997-11-17 1998-12-22 Abbott Laboratories Chemical synthesis of 6-O-alkyl erythromycin A
IL135792A0 (en) * 1997-12-01 2001-05-20 Abbott Lab 6-o-alkyl derivatives of erythronolide b
US5932710A (en) 1997-12-01 1999-08-03 Abbott Laboratories Process for preparing 6-O-alkyl-9-oxime erythromycin B
US5892008A (en) 1997-12-16 1999-04-06 Abbott Laboratories Process for the preparation of 6-O-methyl erythromycin a using 9-hydroxy erythromycin derivatives
KR100377159B1 (ko) 1998-09-09 2003-08-19 한미약품공업 주식회사 잔류 용매가 없는 클라리스로마이신의 결정형 2의 제조 방법
CA2282066C (en) * 1999-06-29 2010-09-07 Smithkline Beecham Corporation Methods of use of quinolone compounds against atypical upper respiratory pathogenic bacteria
KR100322313B1 (ko) * 1999-10-21 2002-02-06 민경윤 클라리스로마이신 결정형 2의 제조방법 및 이에 사용되는 클라리스로마이신 포르메이트
DE19950781A1 (de) * 1999-10-21 2001-04-26 Knoll Ag Mehrteiliges Etikett für Durchdrückpackungen, seine Herstellung und Verwendung
KR100336447B1 (ko) * 1999-11-24 2002-05-15 민경윤 클라리스로마이신의 개선된 제조방법
KR20020070991A (ko) * 1999-12-16 2002-09-11 테바 파마슈티컬 인더스트리즈 리미티드 클라리트로마이신 다형체 및 신규의 다형체 ⅳ의 제조 방법
HUP0204252A3 (en) * 2000-01-11 2003-04-28 Teva Pharma Process for preparing clarithromycin polymorphs and pharmaceutical compositions containing them
WO2001064224A1 (en) * 2000-02-29 2001-09-07 Teva Pharmaceutical Industries Ltd. Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same
MXPA02008861A (es) * 2000-03-15 2003-02-10 Hanmi Pharm Ind Co Ltd Metodo para preparar claritromicina de cristales de forma ii.
US6488962B1 (en) * 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
IN192748B (sh) * 2000-08-29 2004-05-15 Ranbaxy Lab Ltd
ES2195727B1 (es) * 2001-07-05 2005-03-01 Ercros Industrial, S.A. Un procedimiento para la obtencion de claritromicina.
WO2003017981A1 (en) * 2001-08-29 2003-03-06 Ranbaxy Laboratories Limited Controlled release formulation of clarithromycin or tinidazol
CA2481271A1 (en) * 2002-04-03 2003-10-09 Ranbaxy Laboratories Limited Clarithromycin formulations having improved bioavailability
AU2003245504A1 (en) * 2002-06-14 2003-12-31 Andrx Corporation Pharmaceutical compositions for drugs having ph-dependentsolubility
US7063862B2 (en) * 2003-06-03 2006-06-20 Biokey, Inc. Pharmaceutical composition and method for treating
US20050053658A1 (en) * 2003-09-09 2005-03-10 Venkatesh Gopi M. Extended release systems for macrolide antibiotics

Also Published As

Publication number Publication date
KR20030047873A (ko) 2003-06-18
EP1313486A1 (en) 2003-05-28
SK13722002A3 (sk) 2003-08-05
PL366021A1 (en) 2005-01-24
US20060205683A1 (en) 2006-09-14
US6617436B2 (en) 2003-09-09
CZ20023167A3 (cs) 2003-10-15
AU2001225787C1 (en) 2006-09-21
CA2401571A1 (en) 2001-09-07
WO2001064224A1 (en) 2001-09-07
IS6531A (is) 2002-08-28
US7101858B2 (en) 2006-09-05
AU2578701A (en) 2001-09-12
US20010037015A1 (en) 2001-11-01
JP2004509062A (ja) 2004-03-25
IL151496A0 (en) 2003-04-10
US20030216556A1 (en) 2003-11-20
HRP20020709A2 (en) 2004-12-31
HUP0302466A2 (hu) 2003-11-28
AU2001225787B2 (en) 2005-12-08

Similar Documents

Publication Publication Date Title
YU64202A (sh) Postupak za pripremanje klaritromicina i intermedijera klaritromicina, klaritromicina u osnovi bez oksima i farmaceutskog preparata koji ga sadrži
BG103673A (en) 3'-n-oxide, 3'-n-dimethylamine, 9-oxime derivatives of erythromycin a
CA2417825A1 (en) 6.alpha., 9.alpha.-difluoro-17.alpha.-`(2-furanylcarboxyl)oxy!-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4,-diene-17-carbothioic acid s-fluoromethyl ester as an anti-inflammatory agent
PT1254146E (pt) Processos de preparacao de polimeros de claritromicina e novo polimorfo iv
AU5220900A (en) Antimicrobial siloxane quat formulations and the production and use thereof
CA2447175A1 (en) Use of estrogen compounds to increase libido in women
CA2387361A1 (en) Crystal form 0 and form ii of clarithromycin and uses thereof
AU2003273413A1 (en) Pharmaceutically active oligosaccharide conjugates
CA2657483A1 (en) Macrolide synthesis process
PL367814A1 (en) 4,5-dihydro-1h-pyrazole derivatives having potent cb1-antagonistic activity
CA2228472A1 (en) Tablets containing anion exchange resin
WO2004011477A3 (en) 6,11-4-carbon bridged ketolides
WO2004082581A3 (fr) Application a titre de medicaments de derives de cholest-4-en-3- one, compositions pharmaceutiques les renfermant et nouveaux derives
PL348607A1 (en) Novel intermediates, process for preparing macrolide antibiotic agent therefrom
CA2429639A1 (en) Stable azithromycin monohydrate
EP0802228A3 (en) Silicone compositions and uses thereof
MEP88408A (en) Pharmaceutical compositions containing oligosaccharides and preparation thereof
CA2405892A1 (en) Substituted caprolactam carbonates and ethers and their use as anti-tumor agents
CA2533301A1 (en) 7-carboxymethyloxy-3', 4', 5-trimethoxy flavone monohydrate, the preparation method and uses thereof
EA200000172A3 (ru) Способ получения стимуляторов секреции гормонов роста
AP2002002494A0 (en) Hygromycin derivatives.
EP1288280A3 (en) Use of tertiary alcohols or esters as perfuming ingredients
CA2382106A1 (en) Steroids, their preparation, pharmaceutical compositions thereof and uses of the compounds
IL147728A0 (en) Method for making debromohymenialdisine and analogs thereof
WO2001018028A8 (de) Neue c-13-substituierte estra-1,3,5(10)-trien-3-yl-sulfamate, verfahren zu deren herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen zur hemmung von östron sulfatase